The Kim lab (KIM LAB AT VUMC-HEM/ONC) is in the division of Hematology/Oncology, the department of Medicine at Vanderbilt University Medical Center. The Kim lab is also affiliated with Vanderbilt Center for Immunobiology (VCI) and Vanderbilt Institute for Infection, Immunology and Inflammation (VI4). Dr. Kim (PI) is a physician who treats leukemia/lymphoma/myeloma patients using chemotherapy and stem cell transplantation. Dr. Kim is also an immunologist who is interested in tumor immunology and transplant immunology. We are looking for enthusiastic students and post-doctoral fellows.
Medicine (Hem/Onc) | |
1. Overcoming immune evasion in leukemia: Recently, immune checkpoint blockades, including anti-programmed cell death protein 1 (PD-1) therapy, have shown unprecedented clinical efficacy in some solid tumors. However, the response rate to immune checkpoint blockades in myeloid leukemia has been disappointing. The failure of anti-PD-1 therapy in myeloid leukemia suggests that immune evasion in A myeloid leukemia may be attributed to the expression of unique co-inhibitory molecules outside the PD-1–PD ligand 1 (PD-L1) axis. We are investigating to find novel relevant co-inhibitory molecules besides PD-1¬–PD-L1 in human myeloid leukemia and study the role of those co-inhibitory molecules in mouse models including humanized mice. |
|
The experience about animal experiments and multi-color flow cytometry is required. Some candidates who have experience for molecular biology, CRISPR-Cas9 design, 'R' are preferred. |
|
Tae Kon (TK) Kim : tae.k.kim@vumc.org : (615) 875-2453 |
|
2021-05-17 18:54:08 |